Accessibility Menu
Climb Bio logo

Climb Bio(NASDAQ) ELYM

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-8%
5 Year-49%
1 Year+516%
1 Month+15%
N/A
Climb Bio last closing stock price
MetricPriceDate
Last closeUSD 13.732026-08-31
Climb Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.28%USD 16.402026-08-24
1 month+15.38%USD 11.902026-07-31
3 month+22.59%USD 11.202026-06-02
Year to date+243.25%USD 4.002025-12-31
1 year+515.7%USD 2.232025-08-29
3 year+418.11%USD 2.652023-09-01
5 year-48.96%USD 26.902021-09-01
Since inception-8.36%USD 15.902021-08-10

Climb Bio Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$57.62M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 12, 2024

ELYM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Climb Bio

Climb Bio helps people with serious immune system diseases. It makes new drugs that stop the body from attacking itself. The company works to solve rare kidney and blood problems.

Tools for Targeting Disease

  • Budoprutug IV: Intravenous treatment designed to remove B cells that cause the body to attack itself; currently testing for kidney and blood disorders.
  • Budoprutug SC: Under-the-skin version of the lead drug designed for easier patient use; early tests showed it removes B cells as effectively as the intravenous form.
  • CLYM116: Lab-made antibody that blocks signals linked to kidney damage; currently in early safety trials with healthy volunteers.

Strategic Moves and Fresh Capital

  • Rebranded as Climb Bio in Oct. 2024 to focus on autoimmune treatments.
  • Raised $103.4 million in net proceeds through a private placement in April 2026.
  • Acquired worldwide rights to budoprutug for all uses except for cancer treatments.
  • Licensed CLYM116 for development in most global markets excluding mainland China, Hong Kong, Macau, and Taiwan.

What Makes the Science Different

The company focuses on removing specific immune cells that trigger autoimmune diseases. Its strategy involves developing both intravenous and under-the-skin versions of its medicine to provide more options for patients.

Tracking the Clinical Costs

  • Research and development expenses were $9.7 million for the three months ended June 30, 2026, up from $6.6 million year over year.
  • Net loss was $13.5 million for the three-month period ended June 30, 2026, compared to $8.7 million in 2025.
  • Cash, cash equivalents, and marketable securities reached $239.2 million as of June 30, 2026.
  • General and administrative expenses rose to $11.5 million for the six-month period ended June 30, 2026, up from $9.8 million year over year.

Bottom Line

Climb Bio has evolved from its origins as Eliem Therapeutics to focus on a targeted pipeline of autoimmune therapies. The company maintains a cash balance of $239.2 million to support operations into the second half of 2028.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

28

CEO

Aoife M. Brennan, MD

Website

www.climbbio.com

Headquarters

Redmond, WA 98053, US

ELYM Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-31.79%

Return on Capital

-42.16%

Return on Assets

-23.40%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$64.76M

EBITDA

-$4.74M

Operating Cash Flow

-$52.70M

Capital Expenditure

-$369.00K

Free Cash Flow

-$53.07M

Cash & ST Invst.

$183.12M

Total Debt

$1.31M

Climb Bio Performance Analysis

Climb Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Climb Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Climb Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.72-13.3%
20232023-12-31USD -1.30-24.3%
20242024-12-31USD -1.5317.9%
20252025-12-31USD -0.88-42.5%
Climb Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-46.2%
Q42025-12-31-31.6%
Q12026-03-3120.0%
Q22026-06-3010.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

9

N/A

Net Income

-$13.50M

-55.8%

EBITDA

-$13.50M

-69.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$183.12M

+116.2%

Total Debt

$1.31M

+105.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$813.00K

+95.0%

Short Term Debt

$501.00K

+125.7%

Return on Assets

-23.40%

N/A

Return on Invested Capital

-26.94%

N/A

Free Cash Flow

-$10.81M

+3.7%

Operating Cash Flow

-$10.55M

+5.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CKPTCheckpoint Therapeutics, Inc.
$4.26+0.00%
SCPHscPharmaceuticals Inc.
$5.67+0.00%
RVNCRevance Therapeutics, Inc.
$3.65+0.00%
VIGLVigil Neuroscience, Inc.
$8.05+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About ELYM

What is the current price of Climb Bio?

Climb Bio is trading at N/A per share.

What is the 52-week range for Climb Bio?

Over the past 52 weeks, Climb Bio has traded between N/A and N/A.

How much debt does Climb Bio have?

As of the most recent reporting period, Climb Bio reported total debt of $1.31M.

How much cash does Climb Bio have on hand?

Climb Bio reported $44.11M in cash and cash equivalents in its most recent financial results.

What is Climb Bio’s dividend yield?

Climb Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services